News & insights

OMass Therapeutics to Present New Preclinical Data For its Best-in-Class MC2 Program at ENDO 2025

• Pre-clinical companies
• OMass Therapeutics

Northern Gritstone invests in Manchester spinout Apini

Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease

• Clinical companies
• Quell Therapeutics

Beacon Therapeutics Strengthens Leadership Team with the Appointment of Dr. Daniel Chung as Chief Medical Officer

Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson’s Disease at 2025 GBA1 Meeting

• Late-stage clinical companies
• Spur Therapeutics

iOnctura bolsters leadership team with new appointments

• Clinical companies
• iOnctura